|
 
|
|
|
DISEASE: Cutaneous: Kaposi's
Select a REGIMEN:
DISEASE: Cutaneous: Kaposi's
REGIMEN: ABV
-
DOXORUBICIN [DOX] 40 mg/m2 IV...D1
Caution: Monitor cumulative dose (cardiac toxicity)
BLEOMYCIN [BLEO] 15 units/m2 IV...D1,15
Caution: Monitor cumulative dose (pulmonary toxicity)
VINBLASTINE [VLB] 6 mg/m2 IV...D1
CYCLE: 28 days
REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little,
Brown & Co. 1991; 373.
DISEASE: Cutaneous: Kaposi's
REGIMEN: IFN-2a
-
IFN-2a [IFN-2a] 20 MU/m2 per day
IM/SC...
D1-28
Then if responding 20 MU/m2 IM 3x/wk dose escalation: 3 MU IM/SC D1; 9 MU IM/SC D2; 18 MU IM/SC D3-5; 36 MU or 20 MU/m2 daily
CYCLE: None
REFER: Roferon-A (R) (interferon alfa-2a, recombinant), Roche Labs.
PHYSICIANS DESK REFERENCE 49th Ed. Montvale,NJ; 1995;2055.
DISEASE: Cutaneous: Kaposi's
REGIMEN: VCR-VLB
-
VINCRISTINE [VCR] 2 mg IVB...q2wks
Odd weeks - Maximum dose is 2 mg. (FOR PROOFING ONLY: maximum dose used by program will be 2 mg)
VINBLASTINE [VLB] .1 mg/kg IVB
Week 2 then q2wks even weeks
CYCLE: None
REFER: Kahn J, et al: PROC ASCO 1990; 9:A3
DISEASE: Cutaneous: Kaposi's
REGIMEN: VP-16
-
ETOPOSIDE [VP-16] 150 mg/m2 per day
IV/4-6hr...
D1-3
CYCLE: 28 days
REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed.
Little, Brown & Co. 1991; 373.
|
|
Medicine OnLine and UltiTech have no liability for content or goods on the Internet except as set forth in the Terms and Conditions of service. Please read the Disclaimer of Warranties before using information contained in this section. © Copyright 1995-2000 UltiTech, Inc. All Rights Reserved. |
| [ Top Of Page | Regimens Index | DoseCalc Index ] |
|